

Supporting Information for

Cyclic versus noncyclic chelating scaffold for ^{89}Zr -labeled ZEGFR:2377 affibody bioconjugates targeting epidermal growth factor receptor overexpression

Dominik Summer^{†‡}, Javad Garousi^{§‡}, Maryam Oroujeni^{§‡}, Bogdan Mitran[¶], Ken G. Andersson[#], Anzhelika Vorobyeva[§], John Löfblom[#], Anna Orlova[¶], Vladimir Tolmachev[§] and Clemens Decristoforo^{†,*}

[†]Department of Nuclear Medicine, Medical University Innsbruck , Anichstrasse 35, A-6020 Innsbruck, Austria; [§]Institute of Immunology, Genetic and Pathology, Uppsala University, SE-75185 Uppsala; [¶]Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, SE-751 83 Uppsala, Sweden; [#]Division of Protein Technology, KTH Royal Institute of Technology, SE-10691 Stockholm

***Corresponding Author**

E-mail: Clemens.Decristoforo@i-med.ac.at; Tel: +4351250480951; Fax:+435125046780951

TABLE OF CONTENTS

Supporting Figures

ESI-MS spectra of FSC-ZEGFR:2377	3
Autoradiography and hematoxylin and eosin staining of EGFR overexpression targeted with ^{89}Zr -FSC-ZEGFR:2377	4




Figure S1: ESI-MS spectra of FSC-ZEGFR:2377 (8352.12Da measured; 8352Da calculated)




Figure S2: Representative autoradiography (A) and hematoxylin and eosin staining (B) of the same A431 tumor section obtained at 24 h after injection of ^{89}Zr -FSC-ZEGFR:2377.

Panels C and D show magnified areas of the section B.